Finance

Lists
Why is AKTS up 2,31%?
Dive Deeper
AKTS:NASDAQ
Aktis Oncology Inc
18,15 $
+2,31%
(+0,41) 1D
18,15 $
0,00% (0,00)
After hours
Closed: 9 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKTS...
Open
17,74 $
High
18,21 $
Low
17,58 $
Mkt. cap
975,50 млн
Avg. vol.
426,64 м.
Volume
361,04 м.
52-wk high
34,19 $
52-wk low
14,72 $
EPS
-1,42 $
Shares outstanding
53,75 млн
No. of employees
79
Open
17,74 $
High
18,21 $
Low
17,58 $
Mkt. cap
975,50 млн
Avg. vol.
426,64 м.
Volume
361,04 м.
52-wk high
34,19 $
52-wk low
14,72 $
EPS
-1,42 $
Shares outstanding
53,75 млн
No. of employees
79
News stories
From web sources and news partners
About Aktis Oncology Inc
CEO-
Employees79
Founded2020
HeadquartersБостон, Массачусетс, Америка Құрама Штаттары
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to AKTS in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AKTS in the last 3 months.
Highest
Current 18,15 $
40,00 $ (+120,39%)
Average
35,80 $ (+97,25%)
Lowest
33,00 $ (+81,82%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Buy
Maintained
35,00 $
+92,8%
10/02/2026
Jeff Jones
Oppenheimer
Buy
Initiated
40,00 $
+120,4%
09/09/2026
David Lebowitz
BMO Capital
Buy
Initiated
37,00 $
+103,9%
08/18/2026
Unknown Analyst
BMO Capital
Buy
Initiated
37,00 $
+103,9%
08/18/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
34,00 $
+87,3%
08/14/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
33,00 $
+81,8%
08/14/2026
Alexandra Ramsey
William Blair
Buy
Maintained
-
-
08/14/2026
Christopher Raymond
Raymond James
Buy
Initiated
40,00 $
+120,4%
06/16/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
35,00 $
+92,8%
06/03/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Sami Corwin
William Blair
Buy
Initiated
18,75 $
+3,3%
05/02/2026
Unknown Analyst
William Blair
Buy
Initiated
18,60 $
+2,5%
04/29/2026
Andy Hsieh
William Blair
Buy
Initiated
32,00 $
+76,3%
04/29/2026
Jonathan Chang
Leerink Partners
Buy
Initiated
31,00 $
+70,8%
02/03/2026
Last report
2026 ж. 13 там.
Fiscal period
Q2 2026
-0,44 $ / -0,43 $
-2,15%miss
Revenue / Est. (USD)
3,38 млн / 2,58 млн
+30,99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. мау.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
1,60 млн
1,87 млн
3,23 млн
3,38 млн
Cost of goods sold
18,63 млн
16,49 млн
20,04 млн
25,28 млн
Cost of revenue
18,63 млн
16,49 млн
20,04 млн
25,28 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,94 млн
2,75 млн
5,90 млн
7,00 млн
Operating expense
3,94 млн
2,75 млн
5,90 млн
7,00 млн
Total operating expenses
22,56 млн
19,24 млн
25,93 млн
32,28 млн
Operating income
-20,96 млн
-17,38 млн
-22,71 млн
-28,90 млн
Other non operating income
-20,00 мың
-11,00 мың
-3,00 мың
-10,00 мың
EBT including unusual items
-18,08 млн
-15,14 млн
-18,32 млн
-24,14 млн
EBT excluding unusual items
-18,08 млн
-15,14 млн
-18,32 млн
-24,14 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-18,08 млн
-15,14 млн
-18,32 млн
-24,14 млн
Net profit margin
-1 128,98%
-809,52%
-567,86%
-713,48%
Earnings per share
-
-
-0,38
-0,44
Interest and investment income
2,91 млн
2,25 млн
4,38 млн
4,76 млн
Interest expense
-
-
-
-
Net interest expenses
2,91 млн
2,25 млн
4,38 млн
4,76 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,41 млн
-16,68 млн
-22,05 млн
-28,02 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары